Tucatinib for HER2-positive breast cancer

May 9, 2020 0 By FM

The US FDA has approved oral therapy tucatinib for the treatment of advanced HER2-positive breast cancer, including cases of metastases and resistance, Seattle Genetics, Inc announced. 

Tucatinib, which is a small molecule tyrosine kinase inhibitor, is used in combination with trastuzumab and capecitabine and is indicated for patients who have received one or more prior treatments for advanced disease.

HER2-positive breast cancers have too much of HER2, which promotes the growth of cancer cells. More than 25% of women with metastatic HER2-positive breast cancer will develop brain metastases. 

Tucatinib is approved for treatment after patients have taken one or more anti-HER2-based regimens in the metastatic setting.

The FDA approved tucatinib based on the results of a clinical trial enrolling 612 patients who had HER2-positive advanced unresectable or metastatic breast cancer and had prior treatment with trastuzumab, pertuzumab and ado-trastuzumab emtansine (T-DM1).